Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib Plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia
NCT04463953Phase 2Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2020
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib, ixazomib in Waldenström macroglobulinemia (WM), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jun 2020; status: completed.
02
Drugs
zanubrutinibixazomib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT04463953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04463953.